Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Johnson and Johnson

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Patent: 9,295,669

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,295,669
Title:Combination therapy for proliferative disorders
Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difl- uoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.
Inventor(s): Dhingra; Kapil (Sparta, NJ), Higgins; Brian (Fresh Meadows, NY), Kolinsky; Kenneth (Bloomingdale, NJ), Lee; Richard J. (New York, NY), Lestini; Brian (Union City, NJ), Packman; Kathryn (Bloomfield, NJ), Su; Fei (Paramus, NJ)
Assignee: Hoffman La-Roche Inc. (Nutley, NJ)
Application Number:13/313,042
Patent Claims:see list of patent claims

Details for Patent 9,295,669

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Hoffmann-la Roche Inc. PEGASYS peginterferon alfa-2a Injection 103964 2002-10-16 ⤷  Free Forever Trial 2030-12-14
Hoffmann-la Roche Inc. PEGASYS peginterferon alfa-2a Injection 103964 2004-01-07 ⤷  Free Forever Trial 2030-12-14
Hoffmann-la Roche Inc. PEGASYS peginterferon alfa-2a Injection 103964 2011-09-29 ⤷  Free Forever Trial 2030-12-14
Hoffmann-la Roche Inc. PEGASYS COPEGUS COMBINATION PACK peginterferon alfa-2a and ribavirin 125083 2004-06-04 ⤷  Free Forever Trial 2030-12-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.